Introduction
The diagnostic and treatment effectiveness of myasthenia gravis (MG) have been considerably improved in the past 2 decades. In Hungary, guidelines prescribes since 2007 the electromyography (EMG), single-fiber EMG, chest computer tomography and Tensilon test, optionally anti-acetylcholine receptor (AChR) antibody test-and anti-muscle-specific tyrosine kinase (MuSK) antibody test-based diagnostics, and pharmacological, surgical, and immunological therapeutic approaches. Thus, the need for reliable epidemiological methods to monitor the quality of care provided has become more pronounced [1] [2] [3] [4] [5] [6] . To develop these new methods, special approaches are required to develop indicators of the clinical-pathological nature of MG and to account for its rarity [7] .
One of the most important epidemiological tasks is to estimate the incidence and prevalence of MG, and there are many techniques that have been applied for this purpose. In previous studies, the observed estimates vary broadly for both the incidence (0.3-3/100,000) and the prevalence (1.5-17.9/100,000) [2, 5, 7] .
This variability is mostly attributable to the heterogeneity in the occurrence of risk factors and the variable 1 3 effectiveness of institutions involved in MG care: (1) the differences in life span across populations elicit variability in how old age relates to MG; (2) the effectiveness of MG diagnostics, which is also variable, can contribute to the differences in MG incidence; (3) as the effectiveness of therapy influences the life expectancy of patients, the quality of care contributes to the differences in MG prevalence. Additional sources of geographical heterogeneity are (4) genetic variations and (5) differences in environmental exposures [1, 2, 4, 6, 7] . Additionally, it seems probable that the real variability of MG occurrence is augmented by the insufficiencies of epidemiological methods [1] [2] [3] 5] .
Although MG monitoring has to adhere to the standards of rare disease registration, it is obvious that the applied methodology also has to be tailored to the local information technology environment and has to utilize local resources [8, 9] . Consequently, data from several sources, such as clinical and laboratory databases, hospital discharge records (HDR), and research projects, have been used to determine the epidemiological characteristics of MG [2, 5] .
The appropriate quality of indicators is a prerequisite for their routine application. Therefore, basic requirements for databases producing indicators are that they include all episodes meeting the case definition, avoid record duplication, follow patient pathways, produce indicators for subsets of patients, analyze time trends, regulate the availability of data, establish institutional background for reporting, and have an acceptable costutility ratio, in a sustainable manner [8, 9] .
The National Health Insurance Fund (NHIF) in Hungary has the opportunity to test the capabilities of HDRbased MG monitoring because it is the only financing institution covering all of Hungary and it has collected all HDRs from all institutions involved in secondary care for the past 20 years. Technically, the NHIFs applies fee-forservice system based on International Classification of Health Interventions in outpatient care and on Diagnosis Related Groups in inpatient care [10] . However, its database is maintained to manage financing in secondary care, and it has been demonstrated to be effective at solving public health and quality assessment problems [11] [12] [13] [14] [15] .
The primary aims of our study were the following: (1) to assess the usefulness of HDRs by evaluating the concordance of the estimates with those of published studies, and (2) to estimate the Hungarian incidence and prevalence for MG using HDRs. Depending on the ascertained reliability of HDRs, we also aimed to demonstrate the value of HDRs in MG monitoring by (3) computing average age-at-diagnosis (AaD) and (4) describing the impact of regional heterogeneity on the incidence, prevalence, and AaD.
Patients, materials, and methods
The anonymized NHIF HDR database was provided by the National Institute for Quality-and Organizational Development in Healthcare and Medicines for the whole country from 2004 to 2009. Records from both outpatient and inpatient services were included. The HDRs of Hungarian adults (≥ 18 years of age) with International Classification of Diseases, 10th revision (ICD-10), code G70.0 for MG were selected utilizing the opportunity that the MG diagnosis in whole country is based on a guideline. The records contained data on patient sex, age, and place of residence as well as the date of admission, the date of discharge, and ICD-10 disease codes. The records with missing data on these characteristics were dropped from the database. The demographic data were supplied by the Central Office for Administrative and Electronic Public Services of Hungary.
The incidence was calculated for 2007. Patients were considered incident cases if they were not registered between 2004 and 2006 (it was assumed that an MG patient could not be missing from secondary care for 3 years), their first record with a G70.0 code was registered in 2007, and an MG-specific episode was documented in 2008 and 2009 (to select out patients with suspected MG not confirmed later). The incidence was computed using this continuous care-adjusted number of incident cases and demographic data.
The distribution of the age of incident cases and the AaD was described. Depending on the normality of the data (checked by the Kolmogorov-Smirnov test), the median (with interquartile ranges, IQRs), or the mean (with standard deviations, SDs), age of incident cases was calculated.
The Age-and sex-standardized incidence and prevalence ratios (SIR and SPR) were calculated for the seven Hungarian regions (Central Hungary, CH population: 2369880.5; Central Transdanubia; CT: 910794.5; Northern Great Plain, NGP: 1228331.5; Northern Hungary, NH: 1018574.5; Southern Great Plain, SGP: 1105957; Southern Transdanubia, ST: 800559.5; and Western Transdanubia, WT: 824672) using national stratum-specific data. The region-specific average AaDs were also determined.
For the incidence, prevalence, SIR, and SPR, 95 % confidence intervals (CIs) were computed. Gender differences between measures were tested with the independent-sample t-test or the Mann-Whitney test, depending on normality. Regional heterogeneity was investigated by the goodness-of-fit chi-square test for SIR and SPR, and by one-way analysis of variance or the Kruskal-Wallis tests with post hoc analysis for AaD, also depending on normality. Test results with p-values < 0.05 were regarded as significant. The Predictive Analytics Software (PASW) Statistics 18.0 program package was used to implement statistical tests.
up until the age of 60 years, where it started to become more frequent among men (Fig. 3) Using goodness-of-fit tests, we found significant regional heterogeneity in the SIR for both sexes (p = 0.037) but not for men (p = 0.173) and women (p = 0.075) separately. The extreme regional SIRs (0.58 and 1.36) differed significantly from the national reference (Fig. 4) .
Although AaD was not associated with the place of residence for both male (p = 0.091) and female patients (p = 0.072), the region-specific average AaDs showed spatial variability for both sexes (p = 0.010). There was a This secondary data analysis did not require ethical permission because the health insurance IDs in the original database maintained by NHIF has been replaced with pseudo-IDs to prevent the violation of patients' rights to data protection before giving the database compiled for our study to the National Institute for Quality-and Organizational Development in Healthcare and Medicines. Due to this indirect data transfer, later, institute could ensure that our study team had no information on the patients' ID at all. Therefore, this study was based on anonymized records, and no ethical approval was required according to national guidelines and those of National Institute for Quality-and Organizational Development in Healthcare and Medicines. A. Foldvari, N. Kovacs, V. Sipos, G. Merth, F. Vincze, M. Szucs, and Janos Sandor were individually approved to analyze the data.
Results
The database contained 336,679 discharge records from 6171 patients. Dropping records with missing data, 6113 patients were eligible for analysis (Fig. 1) . The size of the adult (≥ 18 years) population of Hungary was 8,259,048 in 2007.
The number of incident MG cases was 228 for 2007. There were 92 male (40.35 %) and 136 female (59.65 %) new patients. The median age (IQR) of subjects in the whole sample was 60.00 (41.25-71.75) years, with a nonnormal distribution (p = 0.016). The age distribution was normal for both sexes (male: p = 0.157; female: p = 0.155). The mean (± SD) age for male and female individuals was 63.60 (± 13.59) and 51.92 (± 19.78) years, respectively. The difference between sex-specific means was significant (p < 0.001).
There were 1439 patients who met the criteria for prevalent MG cases. Female (N = 931; 64.70 %) dominancy was observed. The age distribution in the whole sample (p < 0.001), and among both male (p < 0.001) and female individuals (p = 0.002), deviated significantly from normal. The median (IQR) age for men, women, and for both sexes was 66.0 (54-74), 51.0 (37-67), and 57.0 (41-71) years, respectively. Women were significantly younger than men (p < 0.001).
The calculated incidence (95 % CI) of MG among adults was 2.76 (2.40-3.12) per 100,000 inhabitants. The observed incidence was 2.37 (1.89-2.85) and 3.11 (2.59-3.63) among men and women per 100,000 individuals, respectively. The incidence was low for men < 50 years of age and women < 60 years of age and then gradually increased for older ages. The highest incidence was found in the 75-79-year age group in men (12.80/100,000) and in the 80-84-year age group in women (6.56/100,000; Fig. 2 ).
The prevalence (95 % CI) in 2007 was 17.42 (16.52-18.32) per 100,000 inhabitants. The prevalence was significantly lower for men (13.08; 11.95-14.22 per 100,000) than for women (21.28; 19.91-22.64 per 100,000). A higher MG frequency was found in women compared with men The observed demographic distribution of cases was also consistent with the epidemiological nature of MG for the following reasons: (1) more women were detected than men, (2) the occurrence increased with age, (3) the disease was more frequent among younger women than men, (4) male dominancy was observed among older patients, and (5) both the incidence and the prevalence were bimodal for women but not for men. These findings demonstrate that the Hungarian reporting system effectively registers MG cases and thus may be used to develop and improve upon HDR-based indicators.
The AaD, which depends on the incidence and on the effective diagnosis of MG, is scarcely investigated. It is reflected in the low number of publications on this measure. Therefore, a reference value for this indicator cannot be defined. The HDRs of the NHIF ensure the opportunity to compute the average AaDs for different populations. Hungarian-specific average AaDs (63.60 ± 13.59 for men, 51.92 ± 19.78 for women) were a bit higher than those observed in the Emilia-Romagna region (60.20 ± 17.20 for men; 51.76 ± 20.10 for women), in Cambridgeshire, England (70.00 for men, 41.10 for women, and 47.80 for both sexes), and in Estonia (median: 35.3, range: 7-73 years) significant difference between the highest (67 years, IQR: 50-76) and lowest (46 years, IQR: 34-65) regional average AaDs (p = 0.004; Fig. 5) .
Tests of goodness of fit for SPR determined regional differences for men (p < 0.001) and for both sexes (p < 0.001). Significant variability between regions was not found for women (p = 0.102). Two regions differed significantly from the national average in the total sample (SPR = 0.78 and 1.11). Two extreme regions were also identified for men (SPR = 0.64 and 1.28; Fig. 6 ).
Discussion
The observed MG incidence rate was 2.76/100,000 in our nationwide HDR study, which is in accordance with international studies (0.3-3/100,000) [2] . The estimated prevalence was 17.42/100,000, which is also consistent with the published values (1.5-17.9/100,000) [5] . Taking into consideration that the other studies typically used the whole population as the denominator for their calculation of epidemiologic measures and that our HDR study only focused on adults, this comparison is slightly biased. Replacing the adults with the whole population in the denominators, the incidence rates were 1.89/100,000, 2.56/100,000, and 2.24/100.000 for men, women, and both sexes, respectively; the prevalence rates were 10.45/100,000, 17.54/100,000, and 14.15/100,000, respectively. All of these measures were within the range of previous studies. [1, 16, 17] . Altogether, the diagnostic procedures in Hungary seem to be less effective than in reference areas.
All the calculated indicators showed statistically significant regional heterogeneity, which reflects either the variability of risk factors by region or the variability of guideline adherence for MG care. In our analysis, the risk ratio for extreme regions was 2.34 for incidence and 1.43 for prevalence. The difference between the extreme regions for average AaD was 21 years. It seems that the risk of development and the prognosis of MG are not independent of the place of residence of patients and that the observed differences cannot be neglected.
Our results suggest that an HDR-based monitoring system is able to detect the geographical and demographic heterogeneity of basic epidemiological measures of MG. Hence, advantageous properties of HDRs cannot be disregarded when constructing methods for MG monitoring, although this approach is retrospective (having a 3-year latency in our study) [5, 8, 14, 15] . To explore the causes of the heterogeneity of MG, HDR-derived indicators should be developed and incorporated into MG monitoring. In preparation of the use of these indicators, we should more intensively utilize HDRs for their inherent strengths: (1) a legal basis for a minimum common dataset; (2) standardized coding for diseases (diagnoses, comorbidities, and complications), interventions, and patient characteristics (age, gender, place of residence); (3) low resources needed for analysis; and (4) sustainability because of the obligatory nature of reporting. These advantages are more emphasized if HDRs cover a geographical area allowing for the computation of population-based indicators.
The diagnostic and treatment effectiveness of MG have been considerably improved in the past 2 decades, and thus, the need for reliable epidemiological methods to monitor the quality of care provided has become more pronounced. HDRs seem to be useful for developing MG indicators because they adequately estimate epidemiological parameters of MG occurrence.
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